Business Wire

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating ...
Neurology Advisor

Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis

Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.
Healio

Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Healio

FDA approves Ocrevus for relapsing-remitting MS in children aged 10 years and up

The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...
Monthly Prescribing Reference

High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
Monthly Prescribing Reference

Briumvi Approved for Relapsing Forms of Multiple Sclerosis

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...
Yahoo Finance

Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...